Home › Funds › Saturn V Capital Management LP › MNPR
Saturn V Capital Management LP position in MNPR
MONOPAR THERAPEUTICS INC · Health Care
Saturn V Capital Management LP reported holding 311,976 shares of MNPR (MONOPAR THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$28.9M, representing 4.14% of its reported portfolio and ranking #12 among its reported holdings. Saturn V Capital Management LP has disclosed MNPR holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Saturn V Capital Management LP's MNPR position evolved
Saturn V Capital Management LP first disclosed a stake in MNPR in Q3 2025 at 155,370 shares (US$12.7M). The position peaked in Q2 2026 at 311,976 shares, worth US$28.9M. Across 4 filings, Saturn V Capital Management LP increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 311,976 shares valued at US$28.9M — a reduction of -33,650 shares quarter over quarter.. Notable position changes include a 110% increase in Q4 2025 (shares fell 16% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 155.37K | $12.69M | New |
| Q4 2025 | 325.70K | $21.27M | Add |
| Q1 2026 | 345.63K | $18.94M | Add |
| Q2 2026 | 311.98K | $28.89M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MNPR and 13F data
MNPR (MONOPAR THERAPEUTICS INC) is a Health Care company. 84 other funds we track also report a position in MNPR — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$61.8M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$30.0M), Siren, L.L.C. (US$25.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MNPR
- RA CAPITAL MANAGEMENT, L.P. 667.21K sh · $61.78M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 323.75K sh · $29.98M · Q2 2026
- Siren, L.L.C. 270.12K sh · $25.01M · Q2 2026
- ADAR1 Capital Management, LLC 217.59K sh · $20.15M · Q2 2026
- TCG Crossover Management, LLC 203.33K sh · $18.83M · Q2 2026
- Vivo Capital, LLC 90.50K sh · $8.38M · Q2 2026
- Ikarian Capital, LLC 47.86K sh · $4.43M · Q2 2026
- STEMPOINT CAPITAL LP 30.12K sh · $2.79M · Q2 2026
- Ishara Investments LP 12.30K sh · $1.14M · Q2 2026
- Martin Investment Management, LLC 2.33K sh · $215.46K · Q2 2026
More on Saturn V Capital Management LP
FAQ
How long has Saturn V Capital Management LP held MNPR?
Saturn V Capital Management LP has disclosed MNPR holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is Saturn V Capital Management LP's current position in MNPR?
As of Q2 2026, Saturn V Capital Management LP holds 311.98K shares of MNPR (MONOPAR THERAPEUTICS INC), valued at $28.89M, representing 4.14% of its reported portfolio and ranking #12.
Has Saturn V Capital Management LP been buying or selling MNPR?
In the latest 13F filing (Q2 2026), Saturn V Capital Management LP reduced its position in MNPR. The position peaked in Q2 2026 at 311.98K shares.
Which other funds hold MNPR?
Other major institutional holders of MNPR include RA CAPITAL MANAGEMENT, L.P., DEERFIELD MANAGEMENT COMPANY, L.P., Siren, L.L.C., among 84 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.